Cart
sales@molnova.com
Berberine ursodeoxycholate
CAS No. 1868138-66-2
Berberine ursodeoxycholate( —— )
Catalog No. M36122 CAS No. 1868138-66-2
Berberine ursodeoxycholate (HTD1801) is an orally effective hypolipidemic agent, an ionic salt of Berberine and Ursodeoxycholic acid.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 43 | In Stock |
|
| 5MG | 69 | In Stock |
|
| 10MG | 112 | In Stock |
|
| 25MG | 225 | In Stock |
|
| 50MG | 352 | In Stock |
|
| 100MG | 529 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1107 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBerberine ursodeoxycholate
-
NoteResearch use only, not for human use.
-
Brief DescriptionBerberine ursodeoxycholate (HTD1801) is an orally effective hypolipidemic agent, an ionic salt of Berberine and Ursodeoxycholic acid.
-
DescriptionBerberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes.
-
In Vitro——
-
In VivoBerberine ursodeoxycholate shows significant reductions in HbA1c (hemoglobin A1c) levels, mean HbA1c levels decreases by 0.6%.Berberine ursodeoxycholate is ingested in the form of a salt and it is thought that the salt promptly dissociates within the gastrointestinal tract and that Berberine and Ursodeoxycholic acid are differentially absorbed.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1868138-66-2
-
Formula Weight217.69
-
Molecular FormulaC6H8CuN3O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 5 mg/mL (6.87 mM; Ultrasonic (<60°C)
-
SMILESCOc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC.[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC([O-])=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Harrison SA, et al. A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. Nat Commun. 2021 Sep 17;12(1):5503.?
molnova catalog
related products
-
Chrysophanol8-O-β-D-...
Chrysophanol8-O-β-D-(6'-O-malonyl)glucoside
-
pTH (1-37) (human)
pTH (1-37) (human) is a fragment of parathyroid hormone (PTH). pTH (1-37) (human) induces the cAMP formation and increases alkaline phosphatase activity. pTH (1-37) (human) increases growth, bone calcium content, and bone mineral density (BMD) in uremic animals. pTH (1-37) (human) has the potential for the research of osteoporosis.
-
GS-829845
GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life than the parent.
